CSIMarket
 


Geron Corp  (GERN)
Other Ticker:  
 

Cumulative Geron's Quick Ratio for Trailing Twelve Months Period

GERN's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

GERN Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 7.94 % 54.8 % -5.83 % 68.48 % 115.26 %
Y / Y Cash & cash equivalent Growth 60.93 % 69.32 % 128.16 % -5.96 % 10.58 %
Quick Ratio for Trailing Twelve Months Period 4.39 4.06 3.87 2.98 3.45
Total Ranking # 532 # 633 # 737 # 1040 # 972
Seq. Current Liabilities Growth 23.17 % 65.26 % -42.75 % -7.38 % 76.64 %
Seq. Cash & cash equivalent Growth -15.55 % -2.41 % 120.15 % -11.29 % -11.15 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Geron Corp Cash & cash equivalent average soared by 60.93% in III. Quarter year on year, faster than Current Liabilities, this led to increase in in Geron's Quick Ratio for Trailing Twelve Months Period to 4.39, Quick Ratio for Trailing Twelve Months Period remained below Geron Corp average.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 264 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Geron. While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about GERN
Quick Ratio GERN in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 265
Sector # 450
S&P 500 # 677


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
27.77 11.3 2.98
(Mar 31 2019)   (Dec 31 2022)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Cerevel Therapeutics Holdings Inc   11.90 
Xenetic Biosciences Inc   11.68 
Metacrine Inc   11.65 
Caladrius Biosciences Inc   11.53 
Inozyme Pharma Inc   11.53 
Dianthus Therapeutics Inc   11.39 
Cytokinetics Incorporated  11.36 
Trevi Therapeutics Inc   11.34 
Prothena Corporation Public Limited Company  11.24 
Annexon Inc   11.21 
An2 Therapeutics Inc   11.15 
Erasca Inc   11.12 
Reneo Pharmaceuticals Inc   11.07 
Milestone Pharmaceuticals inc   11.06 
Acasti Pharma Inc   10.98 
Sage Therapeutics Inc   10.78 
Biomea Fusion Inc   10.74 
Relmada Therapeutics Inc   10.64 
Cogent Biosciences Inc   10.43 
Sinovac Biotech Ltd  10.37 
Point Biopharma Global Inc   10.33 
Kalvista Pharmaceuticals Inc   10.31 
Rocket Pharmaceuticals Inc   10.26 
Kronos Bio Inc   10.11 
Shuttle Pharmaceuticals Holdings Inc   10.06 
Pepgen Inc   9.81 
Centessa Pharmaceuticals Plc  9.79 
Landos Biopharma Inc   9.76 
Compass Pathways Plc  9.74 
Cormedix Inc   9.72 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com